Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts

Cancer Science

Volumn 100, Issue 11, 2009, Pages 2193-2201

  Kaneko, Michio ^a   Kaneko, Setsuko ^a   Suzuki, Kenshi ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CELECOXIB; IRINOTECAN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CHILD; CONTROLLED STUDY; DIARRHEA; DRUG DOSE COMPARISON; DRUG INTERMITTENT THERAPY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; LOW DRUG DOSE; MALE; MITOCHONDRION; MOUSE; NEUROBLASTOMA; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; TUMOR XENOGRAFT; UPREGULATION; WEIGHT GAIN;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL PROLIFERATION; CHILD, PRESCHOOL; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; INFANT; MALE; MICE; MICE, INBRED BALB C; NEUROBLASTOMA; PYRAZOLES; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 71049144425     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01280.x     Document Type: Article

References (33)

1. Inagaki J, Yasui M, Sakata N. Successful treatment of chemoresistant stage 3 neuroblastoma using irinotecan as a single agent. J Pediatr Hematol Oncol 2005, 27:604-6.
2. Shitara T, Shimada A, Hanada R. Irinotecan for children with relapsed solid tumors. Pediatr Hematol Oncol 2006, 23:103-10.
3. Kushner BH, Kramer K, Modak S. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol 2006, 24:5271-6.
4. Kiyota N, Tahara M, Fujii S. Nonplatinum-based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma: a retrospective analysis of 12 cases. Cancer 2008, 112:885-91.
5. Bomgaars LR, Bernstein M, Krailo M. Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2007, 25:4622-7.
6. Vassal G, Giammarile F, Brooks M. A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Société Françaīse d'Oncologie Pédiatrìque (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG). Eur J Cancer 2008, 44:2453-60.
7. Kaneko S, Ishibashi M, Kaneko M. Vascular endothelial growth factor expression is closely related to irinotecan-mediated inhibition of tumor growth and angiogenesis in neuroblastoma xenografts. Cancer Sci 2008, 99:1209-17.
8. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (Part 1). J Natl Cancer Inst 1998, 90:1529-36.
9. Hung WC. Anti-metastatic action of non-steroidal anti-inflammatory drugs. Kaohsiung J Med Sci 2008, 24:392-7.
10. Pai R, Soreghan B, Szabo IL. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002, 8:289-93.
11. Tsujii M, Kawano S, Tsuji S. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93:705-16.
12. Lin MT, Lee RC, Yang PC. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2001, 276:48997-9002.
13. Costa C, Soares R, Reis-Filho JS. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 2002, 55:429-34.
14. Koki AT, Masferrer JL. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control 2002, 9:28-35.
15. Johnsen JI, Lindskog M, Ponthan F. Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res 2004, 64:7210-5.
16. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic and clinical issues. J Natl Cancer Inst 2002, 94:252-66.
17. Gasparini G, Longo R, Sarmiento R. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?. Lancet Oncol 2003, 4:605-15.
18. Gately S, Kerbel R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res 2003, 37:179-92.
19. Gerdes J, Lemke H, Baisch H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984, 133:1710-5.
20. Trifan OC, Durham WF, Salazar VS. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 2002, 62:5778-84.
21. Ponthan F, Wickström M, Gleissman H. Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. Clin Cancer Res 2007, 13:1036-44.
22. Emery P, Zeidler H, Kvien TK. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison. Lancet 1999, 354:2106-11.
23. Clemett D, Goa KL. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000, 59:957-80.
24. Solomon SD, McMurray JJ, Pfeffer MA. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071-80.
25. Solomon SD, Wittes J, Finn PV. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008, 117:2104-13.
26. White WB, Faich G, Borer JS. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 2003, 92:411-8.
27. Caldwell B, Aldington S, Weatherall M. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006, 99:132-40.
28. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006, 296:1633-44.
29. Howes LG. Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice?. Ther Clin Risk Manag 2007, 3:831-45.
30. Kardosh A, Wang W, Uddin J. Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo. Cancer Biol Ther 2005, 4:571-82.
31. Kardosh A, Soriano N, Liu YT. Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib. Blood 2005, 106:4330-8.
32. Pyrko P, Soriano N, Kardosh A. Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol Cancer 2006, 5:19-34.
33. Eggert A, Ikegaki N, Kwiatkowski J. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 2000, 6:1900-8.